The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...
One concern about the GLP-1 class of metabolic disorder drugs is that the weight patients lose includes muscle as well as fat. BioAge Labs wants to test whether its experimental medication, dosed ...
The weight-loss drug market is already enormous, but could nearly double in size by 2035. BioAge Labs is still years away from revenue and even more years away from actual profits. Investors should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results